Inhibition of this kinase by the experimental drug D4476, combined with clinically approved proteasome inhibitors, accumulates nuclear FOXO4 to perturb the growth of RAS-mutant cancer cells by promoting apoptosis induction. Here, FOXO4 is linked to cancer.